Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation
Stopped early · Phase 4
Conditions studied: Hypertension, Cardiac Transplantation
In brief
The purpose of this study is to evaluate the safety and efficacy of the blood pressure medication, aliskiren, in heart transplant patients. In terms of safety, the investigators will evaluate the blood levels of aliskiren and determine if aliskiren alters the blood levels of the anti-rejection medication, cyclosporine, in these patients. In terms of efficacy, the investigators will determine how well aliskiren lowers blood pressure in heart transplant patients.
Key facts
- Study ID
- NCT01235910
- Run by
- University of Colorado, Denver
- People needed
- 1
- Starts
- 2011-05-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2018-06-29
Who can join
Age: 21 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 6 months or more since cardiac transplant
- Clinically stable from a transplant perspective
- Maintained on a stable immunosuppressant regimen containing cyclosporine + an antiproliferative agent (e.g., azathioprine, mycophenolate), +/- an oral steroid
- Hypertension, as defined by a seated average systolic blood pressure of ≥ 140 mm Hg and a seated average diastolic blood pressure of ≥ 90 mm Hg, based on 3 separate measurements, spaced 2 minutes apart.
You may not qualify if…
- Clinical instability from a cardiac transplant perspective
- Contraindications to aliskiren therapy
- Conditions that may increase the risk of aliskiren adverse effects
- Severe hypertension
- Concomitant medications known to increase or decrease aliskiren plasma exposure.
Where it is running
- University of Colorado Denver — Aurora, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.